Jagsonpal Pharmaceuticals Limited — Updates, 23-10-2024: Press Release

Jagsonpal Pharmaceuticals Limited reported robust financial results for Q2FY25, with revenues of ₹747 million, reflecting a 29.2% growth year-over-year. Operating EBITDA increased 46% to ₹184 million, resulting in a margin of 24.6%. Net profit rose 53% to ₹114 million, achieving a net profit margin of 15.3%. The company has also approved a stock split, reducing face value from ₹5 to ₹2, pending shareholder approval. A conference call to discuss these results will be held on October 24, 2024.